HEALWELL AI & WELL Health Introduce WELLTRUST to Advance Ethical, AI-Driven Clinical Trial Recruitment

WELLTRUST enables individuals receiving care at WELL clinics to provide explicit, revocable consent for their health information to be reviewed for research outreach.

HEALWELL AI and WELL Health have launched WELLTRUST, a consent-first data governance and patient identification platform designed to accelerate AI-powered clinical trial recruitment across WELL-operated clinics in Canada while safeguarding patient privacy and autonomy.

WELL Health Technologies, a Canadian technology-enabled healthcare provider operating a broad outpatient clinic network, has partnered with HEALWELL AI, a company focused on preventative care and AI-enabled clinical decision support.

Through WELLTRUST, both organizations are formalizing a structured pathway that allows patients to voluntarily opt in to being contacted about clinical research opportunities without disrupting their routine care.

At its core, WELLTRUST enables individuals receiving care at WELL clinics to provide explicit, revocable consent for their health information to be reviewed for research outreach. Patients who choose not to participate continue to receive care as usual.

The first commercial application of WELLTRUST combines WELL Health’s clinical footprint with HEALWELL AI’s DARWEN AI platform. DARWEN is designed to analyze structured and unstructured clinical data to help identify individuals who may be appropriate candidates for specific interventions.

Within WELLTRUST, the system is being used to identify high-fit patients with chronic, rare, or complex conditions who have already consented to research outreach, to improve clinical trial recruitment efficiency.

Dr Alexander Dobranowski, President of HEALWELL AI, commented, "WELLTRUST embodies our commitment to responsible and impactful AI in healthcare. By integrating HEALWELL's data and AI capabilities directly into WELL's clinical environment, we are creating an advanced AI-powered ethical patient identification and research acceleration platform. This will accelerate research and patient access to potentially life-saving innovations while respecting high standards of privacy and patient autonomy."

The platform also incorporates unified privacy, consent, and governance controls aligned with Canadian regulatory standards. This structure is intended to facilitate compliant collaboration with pharmaceutical sponsors, research organizations, and clinical trial networks, while ensuring that patient rights remain central to the process.

Dr Michael Frankel, Chief Medical Officer of WELL Health, added, "This launch marks a major step forward in our mission to empower patients and improve healthcare outcomes through the use of technology. WELLTRUST allows patients to participate in research to accelerate the next generation of therapeutics and diagnostics in a safe, transparent way. WELLTRUST enables partners in the life sciences ecosystem to work with a scalable, consent-driven data infrastructure. We are proud to formalize this next phase of innovation through our collaboration with HEALWELL."

Beyond trial recruitment, WELLTRUST has been designed as a foundation for future applications, including real-world evidence generation and expanded clinical decision support capabilities.

Stay tuned for more such updates on Digital Health News